RÁČIL, Zdeněk, Martina TOŠKOVÁ, Iva KOCMANOVÁ, Lucie BUREŠOVÁ, Michal KOUBA, Luboš DRGOŇA, Lucia MASÁROVÁ, Tomáš GUMAN, Elena TÓTHOVÁ, Juliana GABZDILOVÁ, Kristina FORSTEROVÁ, Jan HABER, Barbora ŽIAKOVÁ, Eva BOJTÁROVÁ, Monika ROLENCOVÁ, Shira TIMILSINA, Petr CETKOVSKÝ a Jiří MAYER. Micafungin as empirical antifungal therapy in hematological patients: a retrospective, multicenter study in the Czech and Slovak Republics. Leukemia & Lymphoma. London: INFORMA HEALTHCARE, 2013, roč. 54, č. 5, s. 1042-1047. ISSN 1042-8194. Dostupné z: https://dx.doi.org/10.3109/10428194.2012.729057. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1071142, author = {Ráčil, Zdeněk and Tošková, Martina and Kocmanová, Iva and Burešová, Lucie and Kouba, Michal and Drgoňa, Luboš and Masárová, Lucia and Guman, Tomáš and Tóthová, Elena and Gabzdilová, Juliana and Forsterová, Kristina and Haber, Jan and Žiaková, Barbora and Bojtárová, Eva and Rolencová, Monika and Timilsina, Shira and Cetkovský, Petr and Mayer, Jiří}, article_location = {London}, article_number = {5}, doi = {http://dx.doi.org/10.3109/10428194.2012.729057}, keywords = {Hematological malignancy; febrile neutropenia; empirical therapy; micafungin}, language = {eng}, issn = {1042-8194}, journal = {Leukemia & Lymphoma}, title = {Micafungin as empirical antifungal therapy in hematological patients: a retrospective, multicenter study in the Czech and Slovak Republics}, volume = {54}, year = {2013} }
TY - JOUR ID - 1071142 AU - Ráčil, Zdeněk - Tošková, Martina - Kocmanová, Iva - Burešová, Lucie - Kouba, Michal - Drgoňa, Luboš - Masárová, Lucia - Guman, Tomáš - Tóthová, Elena - Gabzdilová, Juliana - Forsterová, Kristina - Haber, Jan - Žiaková, Barbora - Bojtárová, Eva - Rolencová, Monika - Timilsina, Shira - Cetkovský, Petr - Mayer, Jiří PY - 2013 TI - Micafungin as empirical antifungal therapy in hematological patients: a retrospective, multicenter study in the Czech and Slovak Republics JF - Leukemia & Lymphoma VL - 54 IS - 5 SP - 1042-1047 EP - 1042-1047 PB - INFORMA HEALTHCARE SN - 10428194 KW - Hematological malignancy KW - febrile neutropenia KW - empirical therapy KW - micafungin N2 - The objective of this retrospective, multicenter study was to evaluate the efficacy and safety of micafungin as empirical antifungal therapy during febrile neutropenia (FN) in 73 hematological patients from 6 centers in two countries. All patients received 100 mg of micafungin/day. The overall favorable response rate (RR) was 64.8% when the resolution of fever during neutropenia was included in the response criteria and 84.5% when excluded. A significantly lower favorable RR in patients with persistent fever and non-specific pulmonary infiltrates compared to patients with persistent fever only (82.8 vs. 52.4%, respectively; p = 0.011) was not found when resolution of fever was not included in the composite endpoint criteria (93.1 vs. 78.6%, respectively; p = 0.180). Breakthrough fungal disease developed in 2.7% patients. Treatment was discontinued in 16.4% of cases. Only one patient (1.4%) discontinued therapy due to an adverse event. Posaconazole prophylaxis improved favorable RR when defervescence was included as composite endpoint criteria (p = 0.047), but not when it was excluded (p = 0.485). However, neutrophil recovery did not influence favorable RR (p = 0.803 and p = 0.112, respectively). These data suggest that micafungin is safe and effective as an empirical therapy in patients with FN. ER -
RÁČIL, Zdeněk, Martina TOŠKOVÁ, Iva KOCMANOVÁ, Lucie BUREŠOVÁ, Michal KOUBA, Luboš DRGOŇA, Lucia MASÁROVÁ, Tomáš GUMAN, Elena TÓTHOVÁ, Juliana GABZDILOVÁ, Kristina FORSTEROVÁ, Jan HABER, Barbora ŽIAKOVÁ, Eva BOJTÁROVÁ, Monika ROLENCOVÁ, Shira TIMILSINA, Petr CETKOVSKÝ a Jiří MAYER. Micafungin as empirical antifungal therapy in hematological patients: a retrospective, multicenter study in the Czech and Slovak Republics. \textit{Leukemia \&{} Lymphoma}. London: INFORMA HEALTHCARE, 2013, roč.~54, č.~5, s.~1042-1047. ISSN~1042-8194. Dostupné z: https://dx.doi.org/10.3109/10428194.2012.729057.
|